|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
subcutaneous injection
|
|
gptkbp:approves
|
gptkb:2015
gptkb:FDA
|
|
gptkbp:chemical_formula
|
C405 H609 N109 O114 S1
|
|
gptkbp:class
|
PCSK9 inhibitor
|
|
gptkbp:clinical_trial
|
gptkb:DESCARTES_trial
gptkb:FOURIER_trial
gptkb:LAPLACE-2_trial
Phase III
|
|
gptkbp:clinical_use
|
gptkb:atherosclerotic_cardiovascular_disease
gptkb:familial_hypercholesterolemia
|
|
gptkbp:contraindication
|
hypersensitivity to evolocumab
|
|
gptkbp:dosage_form
|
injection
|
|
gptkbp:formulation
|
pre-filled syringe
autoinjector
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Repatha
|
|
gptkbp:indication
|
hyperlipidemia
cardiovascular risk reduction
|
|
gptkbp:ingredients
|
gptkb:evolocumab
|
|
gptkbp:invention
|
2026
|
|
gptkbp:is_a_guide_for
|
gptkb:American_Heart_Association
gptkb:European_Society_of_Cardiology
gptkb:American_College_of_Cardiology
|
|
gptkbp:is_effective_against
|
reduces LDL cholesterol
reduces cardiovascular events
|
|
gptkbp:manufacturer
|
gptkb:Amgen
|
|
gptkbp:marketed_as
|
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
inhibits PCSK9 protein
|
|
gptkbp:patient_education
|
storage instructions
injection technique
side effects awareness
|
|
gptkbp:patient_population
|
adults
children over 10 years
|
|
gptkbp:price
|
approximately $14,000 per year
|
|
gptkbp:research_focus
|
cost-effectiveness
long-term safety
comparative effectiveness
|
|
gptkbp:route_of_administration
|
subcutaneous
|
|
gptkbp:safety
|
not recommended during pregnancy
|
|
gptkbp:side_effect
|
allergic reactions
back pain
injection site reactions
flu-like symptoms
elevated liver enzymes
nasopharyngitis
myalgia
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:trade
|
gptkb:evolocumab
|
|
gptkbp:type_of_care
|
self-administered
|
|
gptkbp:used_for
|
lowering cholesterol
|
|
gptkbp:weight
|
143.2 k Da
|
|
gptkbp:bfsParent
|
gptkb:Regeneron_Pharmaceuticals
gptkb:Amgen
|
|
gptkbp:bfsLayer
|
4
|